Arcturus Therapeutics Holdings Inc. ARCT
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Arcturus Therapeutics Holdings Inc. (ARCT) is a healthcare company listed in the US with a market value of about $241M. In the twelve months to September 30, 2026 it had revenue of $31M and net income of -$87M, a net margin of -285.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 54% a year, a 5-year average ROIC of -26%.
About Arcturus Therapeutics
Arcturus Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $16M in 2018 to $82M in 2025, growth of about 26.6% a year. It was profitable in 1 of the last 8 years in our data. It spends 137% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31M | $82M | $152M | $167M | $206M | $12M | $10M | $21M | $16M |
| Net income | -$87M | -$66M | -$81M | -$30M | $9M | -$204M | -$72M | -$26M | -$22M |
| Free cash flow | -$63M | -$75M | -$60M | -$21M | $24M | -$138M | -$45M | -$7M | -$22M |
| EPS (diluted) | $-3.10 | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 | $-3.55 | $-2.15 | $-2.16 |
| Net margin | -285.9% | -80.2% | -53.1% | -17.8% | 4.5% | -1648.0% | -756.4% | -125.0% | -138.3% |
| ROIC | — | -25.2% | -35.5% | -20.0% | 2.9% | -53.9% | -13.5% | -43.0% | -73.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $23.80, 185% above the current price; targets range from $9.00 to $41.00; the consensus rating is “Strong buy”; expected EPS is $-2.90 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Arcturus Therapeutics pay a dividend?
Not currently.
Is Arcturus Therapeutics a good stock to buy?
We do not give buy or sell advice. Arcturus Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.